Showing results (1991-2000 of 2,045) with videos related to
Sort By:
Pageof 205
Frontiers in Oncology|July 18, 2025
Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02)Hang Yuan, Zhen Li, Guang-Shao Cao, et al.Lancet (London, England)|October 11, 2017
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Narikazu Boku, Taroh Satoh, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 16, 2019
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancerTaroh Satoh, Yoon-Koo Kang, Yee Chao, et al.Nature Communications|April 26, 2017
Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cellsFeng Pan, Thomas S Wingo, Zhigang Zhao, et al.The Lancet. Gastroenterology & Hepatology|June 21, 2024
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Masanori Terashima, Young-Woo Kim, et al.The Lancet. Oncology|January 14, 2022
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|December 22, 2019
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update dataLi-Tzong Chen, Taroh Satoh, Min-Hee Ryu, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 20, 2021
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumabNarikazu Boku, Taroh Satoh, Min-Hee Ryu, et al.Nature Food|May 15, 2026
Agricultural soil microbiomes are structurally and functionally more resistant to warming than adjacent natural ecosystemsShuo Jiao, Haibo Pan, Pablo García-Palacios, et al.Nature|January 14, 2026
Direct observation of the Migdal effect induced by neutron bombardmentDifan Yi, Qian Liu, Shi Chen, et al.Pageof 205